giovedì, 26 novembre 2020
Medinews
20 Luglio 2018

FDA Grants Atezolizumab Combo Breakthrough Designation for Frontline HCC

July 18, 2018 – The FDA has granted atezolizumab a breakthrough therapy designation for use in combination with bevacizumab as a first-line treatment for patients with advanced or metastatic hepatocellular carcinoma (HCC). The designation, which will expedite the development and review of the combination in this setting, is based on a phase Ib study in which independent reviewers determined that at a median follow-up of 10.3 months, atezolizumab/ … (leggi tutto)

TORNA INDIETRO